ASCO 2020：11项东亚研究入选口头报告，17项Poster报告

颇受全球新冠疫情因素，延后于5月末29日~6月末2日在芝加哥举办地的美国临床研习（ASCO）年会今年将首次以线上基本概念举办，这是目前最大规模的线上庆典活动。今天，全会的简述题目公告，共103个sessions，欧美共约11项研究课题跻身口头报告，17项跻身Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或帕尔马替尼加卡培他丰使用HER2+心肌梗死乳腺胰脏（PHOEBE）：一项III期随机飞行测试。

演奏会：心肌梗死乳腺胰脏

所写：欧美医学科学院养老院徐兵河副教授、马飞副教授，武汉大学除此以外养老院胡夕春副教授等

简述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可开刀三阴普遍性乳腺胰脏标准用药后卡培他丰持续节拍放射用药的III期飞行测试（SYSUCC-001）。

演奏会：乳腺胰脏—连续性/地带/借助于用药

所写：中的山大学禁毒中的心王时树森副教授等

简述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用心肌梗死小脑的表型特征来计算小脑脊液中的循环系统DNA样品的权重: 新物件敌对老劲敌

演奏会：新物件解决老问题

所写：郑美芹 郑德兰等

简述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

罗萨非尼对奈及利亚拉非尼作为早期肝线粒体胰脏的梯队用药：一项开放字句、随机、多中的心II/III期飞行测试。

演奏会：十二指肠肠道胰脏—十二指肠冠状动脉、血栓和实乃

所写：四川大学索科利夫卡养老院毕锋副教授、欧美各族人民解放军南开养老院秦叔逵副教授等

简述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

欧美早期肝胰脏病患阿帕替尼主干线用药：一项随机、疗效对应、双盲III期研究课题

演奏会：十二指肠肠道胰脏—十二指肠冠状动脉、血栓和实乃

所写：欧美各族人民解放军南开养老院秦叔逵副教授、四川大学索科利夫卡养老院郑秋副教授等

简述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

早期住院普遍性卵巢胰脏二次线粒体减灭术的一项随机III期飞行测试：SOC1 / SGOG-OV2。

讲座：小儿胰脏症

所写：武汉大学除此以外中的山养老院臧荣余副教授等

简述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈胰脏根治普遍性输卵管切除后借助于用药中的的序贯放放射用药对比之外化学疗法或联动放放射用药（STARS研究课题）：一项随机、对应、开放字句的III期飞行测试。

全会：小儿胰脏症

所写：中的山大学禁毒中的心白云副教授、刘继红副教授等

简述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：借助于吉非替尼对比放射用药使用可切除的EGFR变异的N1-N2期NSCLC-随机III期临床飞行测试的最终各个方面生存研究。

讲座：肺胰脏—非小线粒体连续性-地带/小线粒体/其他腿部

所写：广东省各族人民养老院吴一龙副教授等

简述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR变异寡重新分配非小线粒体肺胰脏病患梯队赖氨酸赖氨酸抑制牵头或不牵头全力前线连续性化学疗法：III期开放字句临床随机飞行测试（SINDAS）的中的期结果（NCT02893332）。

讲座：肺胰脏-非小线粒体重新分配

所写：四川省各族人民养老院曾铭副教授等

简述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序普遍性死亡-1（PD-1）的人源化IgG4酵母菌牵头阿昔替尼使用心肌梗死表皮前列腺癌病患的Ib期研究课题的总生存期和生物；也研究。

讲座：前列腺癌/皮肤胰脏

所写：北京大学养老院郭军、盛锡楠副教授等

简述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全普遍性和结果：常用CAR-T线粒体首次化学物质飞行测试用药住院/难治普遍性T线粒体急普遍性淋巴线粒体帕金森氏症（r/r T-ALL）的安全普遍性和。全会：联合开发中的的用药技术-免疫用药。所写：王时自始等简述：3013剧照：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在早期冠状动脉鳞状线粒体胰脏病患中的的应用：一项随机的开放字句II期飞行测试（ORIENT-2）。全会：十二指肠肠道胰脏-十二指肠冠状动脉胰脏、血栓胰脏和实乃道胰脏所写：徐建明副教授等简述：4511剧照：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异普遍性CAR-T线粒体对髓母线粒体瘤的根除普遍性用药全会：中的枢神经系统所写：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、陈旭东简述：2522剧照。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在早期错配修复不足之处病患中的的应用全会：联合开发中的的用药学-免疫用药所写：沈琳副教授等简述：3021剧照。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART用药住院/难治普遍性ACUTE淋巴线粒体帕金森氏症/淋巴瘤的首例化学物质临床飞行测试全会: 联合开发普遍性用药学-免疫用药所写简介：张明志，陈东等简述：3026剧照: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 科克替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）牵头应使用早期实体瘤病患的Ib期研究课题全会：发展普遍性用药学--水分子靶向药物和生物学所写：龚继芳，沈琳副教授等简述：3523剧照：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin牵头类固醇和nedaplatin用药住院普遍性或心肌梗死冠状动脉鳞状线粒体胰脏（ESCC）病患的II期研究课题。全会：十二指肠肠道胰脏-十二指肠冠状动脉、血栓和实乃道胰脏的研究课题所写：王时志极强，郑玉红，王时德申，王时凤华，任超，谭琼 王时志极强、郑玉红、王时德深、王时凤华、任超、谭琼简述：4522剧照：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全会：十二指肠肠道胰脏-十二指肠冠状动脉胰脏、血栓胰脏和实乃管胰脏的主干线用药所写：宋艳等简述：4524剧照：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种唾液外体内环RNA特征向量使用初始活检时样品高等级胰脏的唾液外体内环RNA特征向量：一项多中的心的回顾普遍性研究课题全会：泌尿上皮细胞胰脏症---胰脏、睾丸胰脏和胰脏所写简介：Liaoyuan Li等简述：5522剧照。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 连续性早期宫颈胰脏并发放射用药后的借助于放射用药全会: 小儿胰脏症所写简介： 郑珉珉等简述：6031剧照：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼用药肝脏髓普遍性胰脏的相关普遍性：基于ALTER01031飞行测试的研究。会话：皮脂腺所写：青岛市养老院高明副教授简述：6526剧照。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、尺寸和比率对安洛替尼用药后病患结局的因素: ALTER01031的亚组研究全会：皮脂腺所写：青岛市养老院高明副教授简述：6527剧照。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA研究计算I-IIIA期非小线粒体肺胰脏（NSCLC）病患术后住院: GASTO1035和GASTO1018的结果全会：肺胰脏-非小线粒体连续性-地带普遍性/小线粒体/小线粒体/其他胸科胰脏症所写：Si-Yu Wang等简述：9023剧照：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小线粒体肺胰脏（NSCLC）中的EGFR赖氨酸赖氨酸抑制的新型耐药系统全会:肺胰脏-非小线粒体心肌梗死肺胰脏所写简介：陈昕，金玲玲，满宇，欧秋香，金兰，薛武，杨少，范敏 陈昕、金玲玲、满宇、欧秋香、金兰、薛武、杨绍、范敏简述：9528剧照：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1飞行测试中的早期前列腺癌总生存的替代终点全会：前列腺癌/皮肤胰脏所写：聂润聪，袁书极强，郑元芳，陈英波，周志伟 聂润聪、袁书极强、郑元芳、陈英波、周志伟简述：10030剧照：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼用药住院或心肌梗死原发普遍性恶普遍性肩胛骨病患的II期研究课题全会： 恶性肿瘤所写：唐丽娜，牛晓辉，王时震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王时琼、蔡启庆、涂崇奇、范正福、杨瑶简述：11525剧照。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在早期恶性肿瘤病患多线用药中的的安全普遍性和。全会：恶性肿瘤所写：姚伟涛，王时家极强，张鹏，王时欣，杜新辉，田志浩，牛晓颖 姚伟涛、王时家极强、张鹏、王时鑫、杜鑫辉、田志超、牛晓英简述：11526剧照：414